Graft-versus-Host Disease
Conditions
Interventions
Trial group:After enrollment, subjects will undergo haploidentical hematopoietic stem cell transplantation and receive the following GVHD prophylaxis regimen:
1. ATG 2.5 mg/kg/day intravenously from D
Sponsors
The first affiliated hospital of anhui medical university
Eligibility
Sex/Gender
All
Age
14 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Hematologic malignancies, including acute/chronic leukemia, myelodysplastic syndromes, etc.; 2. Planned to undergo haploidentical hematopoietic stem cell transplantation; 3. Aged 14 to 65 years, male or female; 4. ECOG Performance Status of 0 to 2; 5. Able to understand and willing to sign the informed consent form for this trial.
Exclusion criteria
Exclusion criteria: 1. Strong positive donor-specific antibody (DSA) (titer > 10^4 MFI); 2. Uncontrolled severe infection or other underlying diseases; 3. Patients with cardiac insufficiency: ejection fraction (EF) = 2 mg/dl, AST > 2.5 times the upper limit of normal, serum creatinine (SCr) > 2.5 mg/dl; 5. Life expectancy < 3 months due to other severe diseases; 6. Patients judged by the investigator to be unsuitable for participation in this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cumulative incidence of acute GVHD;Neutrophil engraftment rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Cumulative incidence of chronic GVHD;Incidence of viral infection;Platelet engraftment rate;Donor chimerism rate;Relapse rate;Non-relapse mortality;Disease-free survival;Overall survival; | — |
Countries
China
Contacts
Public ContactLi Qingsheng
The First Affiliated Hospital of Anhui Medical University
Outcome results
None listed